Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Posted: January 5, 2022 at 2:30 am

– Company plans to focus development of Zygel™ in FXS, ASD and 22q –

Excerpt from:
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Related Posts